310 related articles for article (PubMed ID: 31721068)
1. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Matsuo K; Chavez RD; Barruet E; Hsiao EC
Curr Osteoporos Rep; 2019 Dec; 17(6):387-394. PubMed ID: 31721068
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Diolintzi A; Pervin MS; Hsiao EC
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540775
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
Grgurević L; Novak R; Trkulja V; Hamzić LF; Hrkač S; Grazio S; Santini M
Med Hypotheses; 2019 Oct; 131():109313. PubMed ID: 31443758
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Wentworth KL; Masharani U; Hsiao EC
Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
[TBL] [Abstract][Full Text] [Related]
5. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
6. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
7. Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient.
Grgurevic L; Novak R; Hrkac S; Salai G; Grazio S
Rheumatol Int; 2021 Aug; 41(8):1495-1501. PubMed ID: 34110466
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
[TBL] [Abstract][Full Text] [Related]
9. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
10. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
11. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification.
Kan C; Ding N; Yang J; Tan Z; McGuire TL; Lu H; Zhang K; Berger DMP; Kessler JA; Kan L
Stem Cell Res Ther; 2019 Jan; 10(1):14. PubMed ID: 30635039
[TBL] [Abstract][Full Text] [Related]
12. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.
Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA
Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930
[TBL] [Abstract][Full Text] [Related]
13. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.
Barruet E; Morales BM; Cain CJ; Ton AN; Wentworth KL; Chan TV; Moody TA; Haks MC; Ottenhoff TH; Hellman J; Nakamura MC; Hsiao EC
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429363
[TBL] [Abstract][Full Text] [Related]
14. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
15. Quercetin Attenuates Trauma-Induced Heterotopic Ossification by Tuning Immune Cell Infiltration and Related Inflammatory Insult.
Li J; Sun Z; Luo G; Wang S; Cui H; Yao Z; Xiong H; He Y; Qian Y; Fan C
Front Immunol; 2021; 12():649285. PubMed ID: 34093537
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokine and chemokine expression is associated with heterotopic ossification in high-energy penetrating war injuries.
Evans KN; Forsberg JA; Potter BK; Hawksworth JS; Brown TS; Andersen R; Dunne JR; Tadaki D; Elster EA
J Orthop Trauma; 2012 Nov; 26(11):e204-13. PubMed ID: 22588530
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification.
Kan L; Liu Y; McGuire TL; Berger DM; Awatramani RB; Dymecki SM; Kessler JA
Stem Cells; 2009 Jan; 27(1):150-6. PubMed ID: 18832590
[TBL] [Abstract][Full Text] [Related]
20. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
